Literature DB >> 9390671

Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature.

S J Oh1, E J Dropcho, G C Claussen.   

Abstract

Anti-Hu-associated paraneoplastic sensory neuropathy (PSN) has been reported to be nonresponsive to immunotherapy or cancer therapy. We report 2 patients with anti-Hu-associated PSN who achieved sustained clinical improvement with early and aggressive immunotherapy 10-15 months before the diagnosis of small-cell lung carcinoma. Both had chronic "sensory neuronopathy plus"; in addition to sensory neuronopathy, case 1 had a motor-autonomic dysfunction with encephalopathy, and case 2 had a motor-autonomic dysfunction with swallowing difficulty. These two cases were unusual in that sustained clinical improvement was achieved with early aggressive immunotherapy before the detection of cancer and without any concomitant anticancer therapy or lowering of anti-Hu antibody titer. We believe that early and aggressive immunotherapy should be tried in any patient with anti-Hu-associated PSN, as it may induce sustained clinical improvement.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390671

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  14 in total

Review 1.  Immunological mechanisms in paraneoplastic peripheral neuropathy.

Authors:  J C Antoine
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

2.  Paraneoplastic Diseases of the Nervous System.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

3.  Progress in the management of paraneoplastic neurological disorders.

Authors:  Hamid Sadeghian; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

Review 4.  Sensory Neuronopathies.

Authors:  Allison Crowell; Kelly G Gwathmey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-23       Impact factor: 5.081

Review 5.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

Review 6.  Inflammatory neuropathies: an update on evaluation and treatment.

Authors:  Lisa D Hobson-Webb; Peter D Donofrio
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

7.  Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies.

Authors:  J C Antoine; J F Mosnier; L Absi; P Convers; J Honnorat; D Michel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

8.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.

Authors:  F Keime-Guibert; F Graus; A Fleury; R René; J Honnorat; P Broet; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

9.  Immunomodulatory treatment trial for paraneoplastic neurological disorders.

Authors:  Steven Vernino; Brian Patrick O'Neill; Randolph S Marks; Judith R O'Fallon; David W Kimmel
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

10.  Current therapies for neuromuscular manifestations of paraneoplastic syndromes.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.